Murty N. Arimilli
36 Papers
519 Citations
Murty N. Arimilli is an academic researcher. The author has contributed to research in topics: Adefovir & Prodrug. The author has an hindex of 12, co-authored 36 publications.
Chat about Author
Papers
Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.
Jeng-Pyng Shaw,Cathy M. Sueoka,Reza Oliyai,William A. Lee,Murty N. Arimilli,Choung U. Kim,Kenneth C. Cundy +6 more
TL;DR: A series of prodrugs designed to enhance the oral bioavailability of the antiretroviral agent 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) have been synthesized, including a bis-(acyloxymethyl) ester 2 and a series of bis-(alkoxycarbonyloxyloxymethy) esters 3-9.
150
Antiretroviral Efficacy and Pharmacokinetics of Oral Bis(isopropyloxycarbonyloxymethyl)9-(2-Phosphonylmethoxypropyl)adenine in Mice
Lieve Naesens,N. Bischofberger,Patrick Augustijns,Pieter Annaert,Guy Van den Mooter,Murty N. Arimilli,Choung U. Kim,Erik De Clercq +7 more
TL;DR: The favorable pharmacokinetic profile, marked antiviral efficacy, and low toxicity make bis(POC)-PMPA an attractive oral prodrug of PMPA that should be further pursued in clinical studies with patients infected with human immunodeficiency virus or hepatitis B virus.
147
Patent
Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Murty N. Arimilli,Kenneth C. Cundy,Joseph P. Dougherty,Choung U. Kim,Reza Oliyai,Valentino J. Stella +5 more
- 19 May 1999
TL;DR: In this paper, the structure of esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure OC(R 2 ) 2 OC(O)X(R) a was defined.
138
Mutations in the Nonstructural Protein 3A Confer Resistance to the Novel Enterovirus Replication Inhibitor TTP-8307
Armando M. De Palma,Hendrik Jan Thibaut,Lonneke van der Linden,Kjerstin Lanke,Ward Heggermont,Stephen Ireland,Robert Andrews,Murty N. Arimilli,Taleb H. Al-Tel,Erik De Clercq,Frank J. M. van Kuppeveld,Johan Neyts +11 more
TL;DR: It is hypothesized that TTP-8307 and enviroxime disrupt proper interactions of 3A(B) with other viral or cellular proteins that are required for efficient replication.
Patent
Substituted azole derivatives as therapeutic agents
Adnan M. M. Mjalli,Robert C. Andrews,Ravindra R. Yarragunta,Rongyuan Xie,Govindan Subramanian,Jr. James C. Quada,Murty N. Arimilli,Dharma Rao Polisetti +7 more
- 12 Feb 2004
TL;DR: In this article, the authors provide azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases) and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity.
69